Shamis & Gentile, P.A. is investigating claims on behalf of investors of AVITA Medical, Inc. (“AVITA Medical” or the “Company”) (RCEL). Impacted investors are advised to contact the firm now.
The investigation concerns whether AVITA Medical and certain of its officers and/or directors engaged in securities fraud or other unlawful business practices.
On Aug. 7, 2025, AVITA Medical disclosed that CMS-assigned contractors had failed to price RECELL, resulting in a six-month backlog of unpaid claims and a significant decline in first-half demand. The Company reported that RECELL revenue was approximately $10 million lower than expected, representing about 15% of its 2024 sales. .
On this news, AVITA Medical’s stock price fell $1.13 per share, or approximately 21%, to close at $4.25 on Aug. 8, 2025, on unusually high trading volume.
Shamis & Gentile, P.A. stands out as an advocate for investors who are victims of securities fraud. The firm is committed to securing recoveries for investors who have incurred damages due to false and misleading statements or other corporate misconduct by public companies. Shamis Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise and resources enable the firm to resolve disputes in a wide range of matters including class actions, mass torts and mass arbitrations.
Attorney advertising. Prior results do not guarantee similar outcomes.
